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BACKGROUND: HER2 is an oncogenic receptor, promoting tumour development and disease 
progression in 15-25% of breast cancers. HER2 overexpressing tumours are more aggressive 
and associated with poorer prognosis, thus the receptor is a priority target for anticancer 
therapy. HER2 is notably ‘endocytosis resistant”, frustrating targeting approaches where 
efficacy is contingent on lysosomal delivery e.g. antibody-drug conjugates (ADC) such as 
trastuzumab-emtansine. We extend our recently published research showing that receptor-
antibody clustering induced endocytosis (RACIE) can be strategically used to promote 
lysosomal delivery and degradation of HER2 in breast cancer cells (Moody et al. 2015; Ogris 
and Sami 2015). 
 
MATERIALS AND METHODS: HER2-RACIE was examined in two breast cancer cell lines 
overexpressing this receptor: BT474 and SKBR3 cells. Clustering was achieved by sequential 
application of biotinylated, fluorescently-labelled trastuzumab and streptavidin. Trastuzumab 
was clinically sourced and labelled in-house. Following RACIE, downstream analyses were 
performed: Western blotting to study changes in HER2 levels, activation and downstream 
signalling and to measure the levels of other HER family members, EGFR and HER3. Live cell 
confocal microscopy was conducted to monitor endocytosis. 
 
RESULTS AND DISCUSSION: Examination of HER2 levels at time points up to 48 hr demonstrated 
that after an initial reduction, HER2 levels then recover, potentially allowing for retargeting. 
Investigation of HER2 activation and downstream signalling revealed HER2-RACIE specific 
activation of the MEK/ERK pathway. The levels of HER2 dimerization partners were examined 
and while EGFR levels were unaffected, HER3 was concomitantly downregulated with HER2. 
Highly biotinylated trastuzumab (6.0 biotins per antibody) was compared with low biotin (1.7 
per antibody) for RACIE. The data showed that HER2 and HER3 downregulation was only 
induced by the highly biotinylated trastuzumab while ERK activation was stimulated by both 
antibodies. 
 
CONCLUSIONS: Our data suggest that RACIE, induced by antibodies of sufficient valency, 
represents an effective approach for enhanced delivery of ADCs in HER2+ breast cancer. This 
strategy may also have the potential extend to other receptor targets in a wide range of 
cancers.  
